Asthma is not controlled in almost two thirds of affected children according to the largest ever international survey undertaken in paediatric asthma(1).
This poor result is despite apparently straightforward clinical guidelines and widely available preventative treatments for children with asthma.
Nycomed and Forest Laboratories today announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to
Nycomed agreed with Sanofi-Aventis and Zentiva to purchase 20 branded generic products in several Central and Eastern European countries. The agreement will notably strengthen Nycomed's market position in particular in the Czech Republic and Slovakia. The transaction received approvals from the European Commission and the Czech Antimonopoly Office, and it is expected to be closed in September 2009.
Nycomed today announced that the European Commission has granted marketing authorisation for Instanyl®, its first-in-class intranasal fentanyl spray. Instanyl is aimed at managing breakthrough pain in adult cancer patients already receiving maintenance opioid therapy for chronic pain. It is designed to closely match the typical episodes of breakthrough cancer pain. Nycomed plans to launch the product in 2009.
Nycomed received marketing authorisation from the European Commission for five applications: PANTOZOL Control®, PANTOLOC Control®, PANTECTA Control®, SOMAC Control® and CONTROLOC Control®.
This new OTC medication is intended for short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults as a medicinal product not subject to medical prescription.